Panel Discussion: Evaluating the Diversity of Biomarkers in Development for Psychosis: The Rationale Behind Biomarker Selection & Where They Fit into R&D for Psychosis Therapeutics
Time: 2:30 pm
day: Day One
Details:
Audience Q&A with:
- Alto Neuroscience – Precision Psychiatry PlatformTM
- Monument Therapeutics – Digital Biomarker
